Allbirds Second Quarter 2025 Earnings: Beats Expectations

Explore Allbirds’s Fair Values from the Community and select yours

• Revenue: US$39.7m (down 23% from 2Q 2024).

• Net loss: US$15.5m (loss narrowed by 19% from 2Q 2024).

• US$1.92 loss per share (improved from US$2.45 loss in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 27%.

Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Luxury industry in the US.

Performance of the American Luxury industry.

The company’s shares are down 27% from a week ago.

Before we wrap up, we’ve discovered 3 warning signs for Allbirds (1 is concerning!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.